Latest Safety News

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

NEXTDC’s FY25 results reveal robust financial growth driven by surging AI and cloud demand, alongside a strategic joint venture to expand its Western Sydney data centre footprint.

NEXTDC Limited reported a 6% rise in FY25 revenue and underlying EBITDA, offset by a widened loss due to a $2.9 billion debt refinancing. The company’s strategic expansion in AI-ready data centres and a strengthened $6.4 billion debt facility position it for significant growth.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Bisalloy Steel Group reported steady revenue but strong profit growth and a significant dividend increase for FY25, while outlining ambitious expansion plans for FY26.

Bisalloy Steel Group Limited reported a 24.4% rise in profit after tax to $19.6 million for FY25, driven by strong Armour & Protection steel sales and international growth. The company declared a 16.5 cents per share fully franked final dividend, up 43.5% from last year, while advancing key growth initiatives in Asia and sensor technology.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Advanced Braking Technology Ltd reported a robust 25% revenue increase and a 36% rise in net profit for FY25, driven by international expansion and new product launches.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.